EXCLUSIVE: Data Monitoring Committee Allows BioRestorative's Chronic Lumbar Disc Disease Study To Continue Unchanged
Portfolio Pulse from Vandana Singh
BioRestorative Therapies Inc (NASDAQ:BRTX) has received unanimous approval from the independent Data Safety Monitoring Board (DSMB) to continue its ongoing Phase 2 trial for chronic lumbar disc disease treatment with no changes. The treated patients will receive BRTX-100, a product formulated from autologous hypoxic cultured mesenchymal stem cells and autologous platelet lysate.
June 27, 2023 | 10:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioRestorative Therapies' Phase 2 trial for chronic lumbar disc disease treatment has been approved to continue unchanged by the DSMB. This may positively impact the company's stock price.
The unanimous approval from the independent Data Safety Monitoring Board (DSMB) to continue the Phase 2 trial without changes is a positive development for BioRestorative Therapies. This indicates that the trial is progressing well and may lead to potential FDA approval in the future. As a result, this news may positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100